A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC
- Resource Type
- Journal
- Source
JOURNAL OF THORACIC ONCOLOGY ; OCT 2018, 13 10, pS679-pS679, 1p. Supplement: S- Subject
- Language
- English
- ISSN
- 15561380